Description: Pascal Biosciences Inc, formerly Biommune Technologies Inc, is a Canada-based biopharmaceutical company. The Company is a research and development issuer. The Company is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system. The Company operates in the segment of biotechnology research and development. The Company focuses on cancer, infectious and autoimmune diseases. It offers various technologies, such as Major Histocompatibility Complex I (MHC I), a molecule that transports normal, abnormal and foreign protein fragments (peptides) to the surface of the cells, where the fragments are then exposed to the immune system's T Cells; CD74, a chaperone protein that is involved in the presentation of MHC I and MHC II molecules on cell surfaces, and Calcium Channel Blockers, which are methods and agents that modulate voltage-gated calcium channels.
Home Page: www.pascalbiosciences.com
PAS Technical Analysis
4000 Mason Road
Seattle,
WA
98195-2141
United States
Phone:
206 221 3443
Officers
| Name | Title |
|---|---|
| Mr. Harold H. Forzley C.A. | Chief Financial Officer |
| Dr. Brian W. Bapty Ph.D. | CEO, Pres & Director |
| Mr. Kevin M. Egan M.B.A. | Chief Bus. Officer |
Exchange: V
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 339.7628 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | November |
| Full Time Employees: | 2 |